“We know there are a number of hurdles that countries have to overcome to gain access to our medicines. That is why we have initially selected five pilot countries to identify and come up with operational solutions and then share those learnings with the remaining countries,” Angela Hwang, group president of the Pfizer Biopharmaceuticals Group, said.
